

20th INTERNATIONAL p53 WORKSHOP

WORKSHOP PROGRAM

SickKids Peter Gilgan Centre for Research and Learning, Toronto, ON

April 27- May 1, 2026

Rooms: Gallery, Event Rooms 2a/2b (second floor) and Event Rooms 3a/3b (third Floor)

Registration: 7:00 am to 5:00 pm- April 28-30

Monday, April 27, 2026

3:00 – 6:00pm	Registration	
6:00 - 9:00 pm	Welcome Reception	22nd Floor Patient Support Centre, Hospital for Sick Children

Tuesday, April 28, 2026

7:00 – 8:30am	Sign in and Breakfast	PGRL Gallery
8:30 – 9:15	Introductory remarks and welcome	Org Committee Chairs + Chiefs of Research (SK, UHN, MSH)

Session 1: A tribute to Pierre Hainaut- 9:15-11:30- Moderator: TBD

Emilie Montellier	Determinants of Phenotypic Variability in the Li-Fraumeni Syndrome.	University of Grenoble Alpes
Arnold Levine	The role of the Diversity box and the P2 promoter in Dense Associative Memory of gene expression.	Institute for Advanced Studies, Princeton
Christian Kratz	Research Update from the Li-Fraumeni Syndrome Registry in Germany.	University of Hannover
David Malkin	Exploring the complex relationship of p53 and Li-Fraumeni Syndrome: Translating Discovery Science into the Clinic.	The Hospital for Sick Children
11:30-1:00	Lunch	PGRL Gallery

Session 2: p53 and the Dark Genome-1:00-3:15- Moderator: TBD

Kathleen Burns	Transposable elements and tumor suppressor genes.	Dana-Farber Cancer Institute
----------------	---	------------------------------

John Abrams	p53 Biology Meets Jumping Genes.	UT Southwestern Medical Center
Andrei Gudkov	TBD	Roswell Park Comprehensive Cancer Center
Martin Fischer	Genome regulation by p53.	Otto von Guericke University
Raul Rabadan	Illuminating the Dark Cancer Genome using Foundation Models.	Columbia University
3:15-4:15	<i>Break</i>	<i>PGRL Gallery</i>
Session 3: p53 and Cancer Evolution- 4:15-5:45- Moderator: TBD		
Gigi Lozano	Mutant p53 proteins in tumor evolution and dissemination.	MD Anderson Cancer Center
Scott Lowe	Mimicking p53 for cancer therapy.	Memorial Sloan-Kettering Cancer Center
Giannino Del Sal	Mutant p53 and the Mechanics of Tumor Adaptation: Metabolic, Nuclear, and Immune Interfaces.	University of Trieste, ICGEB, and IFOM
Fritz Vollrath	Elephants in our Room.	Oxford University
END OF DAY 1		
Wednesday, April 29, 2026		
7:00 – 8:00 am	<i>Breakfast</i>	<i>PGRL Gallery</i>
Session 4: Targeting p53- 8:00-10:15- Moderator: TBD		
Kanaga Sabapathy	p53 as a target for cancer prevention and therapy.	Nanyang Technological University
Galina Selivanova	p53, inflammation and microbiome.	Karolinska Institute
Klas Wiman	Novel strategies for targeting missense and nonsense mutant TP53 in cancer.	Karolinska Institute
Andreas Strasser	Which attributes of mutant p53 proteins should be targeted for cancer therapy?	Walter and Eliza Hall Institute of Medical Research
Shelley Berger	Epigenetic pathways as targets in human cancer.	University of Pennsylvania
10:15-11:15	<i>Break</i>	<i>PGRL Gallery</i>
Session 5: p53 Interception and prevention- 11:15-1:00- Moderator: TBD		
Bowen Li	Development of programmable mRNA nanomedicines for precision cancer immunotherapy.	University of Toronto
Jason Berman	Zebrafish Models: Illuminating Cancer Prevention Pathways in p53-Mediated Tumors.	University of Ottawa

Vinod Balachandran	RNA vaccines for Pancreatic cancer.	Memorial Sloan-Kettering Cancer Center
Sarah Blagden	Learning from LungVax, is now the time for LFS-Vax?	Oxford University
Session 6: Presentations from Proffered Abstracts- 1:00-1:45- Moderator: TBD		
1:45-2:30	Lunch	PGRL Gallery
POSTER SESSION #1- 2:30-4:00pm		
Session 7: p53, Immunity and Autoimmunity- 4:00-6:00pm- Moderator: TBD		
Xin Liu	P53, EBV and p53 autoantibodies.	Oxford University
Trevor Pugh	Cell-free DNA for early detection of cancer and immune responses in Li-Fraumeni Syndrome.	Ontario Institute for Cancer Research
Moshe Oren	p53 regulates histone modifications to promote mature luminal identity .	Weizmann Institute of Science
Benjamin Greenbaum	Evolutionary and immune trade-offs yield vulnerabilities for p53.	Memorial Sloan Kettering Cancer Center
Uri Tabori	The role of TP53 mutations in tumor initiation, progression and immune response of replication repair deficient cancers.	The Hospital for Sick Children
END OF DAY 2		
SOCIAL EVENT- WORKSHOP-WIDE DINNER		
Thursday, April 30, 2026		
7:00 – 8:30 am	Breakfast	PGRL Gallery
Session 8: p53 Structure and Function (Wildtype and Mutant)- 8:30-10:15am- Moderator: TBD		
Carol Prives (Keynote talk)	Structural and functional studies of wild-type and mutant p53 proteins.	Columbia University
Ran Kafri	Preventing the onset of cancers in Li Fraumeni Syndrome.	The Hospital for Sick Children
Jim Manfredi	Transcriptional regulation by wild-type and mutant p53.	Mount Sinai School of Medicine
Wei Gu	Understanding the complexity of p53-mediated activities in tumor suppression.	Columbia University
10:15-10:45	Break	PGRL Gallery

Session 9: p53 and Cell Cycle Disruption- 10:45-12:15- Moderator: TBD		
Andrei Budanov	Sestrins in the regulation of different types of cell death.	Trinity College Dublin
Francis Barr	Integrating mitotic checkpoint activation with p53-dependent cell cycle arrest.	Oxford University
Galit Lahav	p53 Dynamics and Decision Making in Single Cells.	Harvard University
Karen Oegma	The mitotic stopwatch intersects with basal p53 activation to control cell proliferation.	University of California- San Diego
12:15-1:30	Lunch	PGRL Gallery
POSTER SESSION #2- 1:30-3:00pm		
Session 10: Presentations from Proffered Abstracts- 3:00-3:45 Moderator: TBD		
Session 11: p53 and Genomic Instability I- 3:45-5:00- Moderator: TBD		
Batsheva Kerem	Hypertranscription caused by P53 deficiency triggers nucleotide insufficiency that induces replication stress and genomic instability.	Hebrew University
Daniel Schramek	Systematic identification of novel intrinsic and extrinsic regulators of wild-type and mutant p53 stability.	Lunenfeld Institute, Mount Sinai Hospital
David Kirsch	p53 regulates metabolism to maintain chromosomal stability.	Princess Margaret Cancer Centre
Session 12: p53 and Genomic Instability II- 5:00-6:00- Moderator: TBD		
Laura Attardi	Deciphering how p53 governs cell state transitions in cancer and injury repair.	Stanford University
Gerry Melino	TBD	University of Tor Vergata
END OF DAY 3		
SOCIAL EVENT- SPEAKER DINNER		
Friday, May 1, 2026		
7:00 – 8:30 am	Breakfast	PGRL Gallery
Session 13: p53 Partners and Interactors - 8:30-10:45- Moderator: TBD		
Maureen Murphy	Making a dumb protein smart: PADI4 citrullinates p53 to enhance tumor suppression.	The Wistar Institute

Tomer Cooks	Out of the cell: extracellular p53-based interactions.	Ben-Gurion University
David Lane	Regulation of the p53 pathway by CDK inhibition, splicing and transcription.	Karolinska Institute
Jean-Christophe Bourdon	What is p53? A Discussion Comparing the Single-Protein Model and the Multi-Isoform Model.	The University of Dundee
Giovanni Blandino	TP53 mutations and cancer resistance.	Regina Elena National Cancer Institute
10:45-11:15	<i>Break</i>	<i>PGRL Gallery</i>
Session 14: p53 and MDM2- 11:15-12:05- Moderator: TBD		
Christine Eischen	Bi-functional MDM2 degrader increases efficacy against mutant p53 cancer.	Thomas Jefferson University
Matthias Dobbstein	Regulator and effector of p53 – the expanding role of MDM2.	University Medical Center Göttingen
Session 15: p53 in the clinic- 12:05-1:00- Moderator: TBD		
Kara Maxwell	P53 hypomorphs - from biology to clinical practice in adults.	University of Pennsylvania
Judy Garber	Clinical Updates from the LiFT UP Project.	Dana-Farber Cancer Institute
POSTER AWARDS CEREMONY AND CLOSING REMARKS (1:00-1:30)		